Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) have earned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $20.6667.

Several equities research analysts have recently weighed in on PHAT shares. Wall Street Zen raised Phathom Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, October 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, October 8th. Guggenheim reissued a “buy” rating and set a $20.00 price objective on shares of Phathom Pharmaceuticals in a research report on Thursday, October 30th. Craig Hallum reaffirmed a “buy” rating and issued a $22.00 target price on shares of Phathom Pharmaceuticals in a report on Friday, October 31st. Finally, HC Wainwright raised their price target on Phathom Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, October 31st.

Phathom Pharmaceuticals Trading Down 2.0%

Phathom Pharmaceuticals stock opened at $14.56 on Friday. The company has a fifty day simple moving average of $12.66 and a 200-day simple moving average of $9.64. The stock has a market cap of $1.04 billion, a P/E ratio of -3.81 and a beta of 0.47. Phathom Pharmaceuticals has a 12-month low of $2.21 and a 12-month high of $16.08.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its quarterly earnings results on Thursday, October 30th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.15. The business had revenue of $49.50 million for the quarter, compared to analysts’ expectations of $47.03 million. Phathom Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Phathom Pharmaceuticals will post -4.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Large investors have recently modified their holdings of the stock. Jones Financial Companies Lllp grew its position in Phathom Pharmaceuticals by 442.6% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,523 shares of the company’s stock valued at $30,000 after buying an additional 2,058 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Phathom Pharmaceuticals in the second quarter valued at about $30,000. Ameritas Investment Partners Inc. increased its stake in shares of Phathom Pharmaceuticals by 39.3% during the second quarter. Ameritas Investment Partners Inc. now owns 4,311 shares of the company’s stock worth $41,000 after acquiring an additional 1,216 shares during the period. CWM LLC raised its holdings in Phathom Pharmaceuticals by 20,997.1% during the first quarter. CWM LLC now owns 7,384 shares of the company’s stock worth $46,000 after purchasing an additional 7,349 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Phathom Pharmaceuticals by 71.9% during the second quarter. BNP Paribas Financial Markets now owns 5,072 shares of the company’s stock worth $49,000 after purchasing an additional 2,122 shares in the last quarter. Hedge funds and other institutional investors own 99.01% of the company’s stock.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.